Press Release
  • Press Release
  • Contact Us
  • Phase 3 Data Show That TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine Significantly Improves Event-Free Survival and Overall Survival in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia

    Times:2021.12.12   Author:CStone

    • TIBSOVO in combination with azacitidine compared to placebo plus azacitidine also demonstrated significant improvement in complete remission rate, complete remission and complete remission with partial hematologic recovery rate and objective response rate
    • Safety profile was favorable and consistent with previously published data
    • Data from the Phase 3 AGILE Trial of patients with previously untreated IDH1-mutated acute myeloid leukemia will be presented in an oral session on Monday, December 13, 2021, and featured in the official press program of the 63rd American Society of Hematology Annual Meeting.


    SUZHOU, China, December 12th, 2021 –The partner of CStone Pharmaceuticals (“CStone”, HKEX: 2616), Servier, today announced Phase 3 data from the global AGILE study demonstrating that TIBSOVO® (ivosidenib tablets) in combination with the chemotherapy azacitidine significantly improved event-free survival and overall survival in adults with previously untreated IDH1-mutated acute myeloid leukemia (AML) compared to azacitidine plus placebo. These data will be presented in an oral session on Monday, December 13, 2021 from 2:45 - 4:15 PM ET, Abstract #697 and featured in the official press program during the 63rd American Society of Hematology Annual Meeting and Exposition.

    Treatment with TIBSOVO in combination with azacitidine demonstrated a statistically significant improvement in event-free survival (EFS) (hazard ratio [HR] = 0.33 [95% CI 0.16, 0.69], 1-sided P = 0.0011) 1,2. In addition, the combination of TIBSOVO with azacitidine showed a statistically significant improvement in overall survival (OS) (HR = 0.44 [95% CI 0.27, 0.73]; 1-sided P = 0.0005), with a median OS of 24.0 months in the ivosidenib + azacitidine arm vs 7.9 months in the placebo + azacitidine arm.

    Servier has an exclusive license agreement with CStone for the development and commercialization of TIBSOVO in Mainland China, Taiwan, Hong Kong, Macau and Singapore. On July 19, 2019, CStone announced that the first patient in China was dosed in AGILE, the global registrational Phase 3 study of ivosidenib. 16 centers in China participated in this study.

    Professor Wang Jianxiang with the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, the Principal Investigator of AGILE in China, said: “AML is a rapidly progressing and life-threatening hematological malignancy. The prognosis is poor in newly diagnosed elderly patients who have conditions that preclude use of intensive induction chemotherapy. For them, our goal of treatment is to prolong overall survival. The impressive clinical benefit following treatment with the TIBSOVO combination will provide a new option for patients with previously untreated IDH1-mutated AML.”

    Dr. Jason Yang, Chief Medical Officer of CStone, said, “We are excited to bring a new treatment option to patients with previously untreated IDH1-mutated AML. These findings demonstrated growing evidence of significant clinical benefits in patients with AML and IDH1 mutations, and it will help advance precision treatment of AML, greatly increase patients’ survival rate. Meanwhile, we plan to communicate with the National Medical Products Administration (NMPA) of China with an aim to bring this innovative treatment to Chinese patients as soon as possible.”

    Additional Study Results

    Investigators reported on results of key secondary endpoints of the AGILE trial including:

    • Complete remission (CR) rate was 47.2% (n=34/72) for TIBSOVO in combination with azacitidine vs. 14.9% (n=11/74) for placebo plus azacitidine (p < 0.0001).
    • CR + complete remission with partial hematologic recovery rate (CR + CRh rate) was 52.8% (n=38/72) for TIBSOVO in combination with azacitidine vs. 17.6% (n=13/74) for placebo plus azacitidine (p < 0.0001).
    • Objective response rate (ORR) was 62.5% (n=45/72) for TIBSOVO in combination with azacitidine vs. 18.9% (n=14/74) for placebo plus azacitidine (p < 0.0001)


    Common all-grade adverse events (AEs) occurring in more than 20 percent of patients receiving TIBSOVO in combination with azacitidine vs. placebo plus azacitidine were nausea (42.3% vs. 38.4%), vomiting (40.8% vs 26.0%), diarrhea (35.2% vs 35.6%), pyrexia (33.8% vs 39.7%), anemia (31.0% vs 28.8%), febrile neutropenia (28.2% vs 34.2%), thrombocytopenia (28.2% vs 20.5%), neutropenia (28.2% vs. 16.4%), constipation (26.8% vs 52.1%) and pneumonia (23.9% vs 31.5%).

    TIBSOVO is currently approved in the U.S. as monotherapy for the treatment of adults with IDH1-mutant relapsed or refractory acute myeloid leukemia (AML), and for adults with newly diagnosed IDH1-mutant AML who are ≥75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy. Recently, TIBSOVO was approved as a first and only targeted therapy for patients with previously treated IDH1-mutated cholangiocarcinoma.

    In China, TIBSOVO was selected in the list of the third batch of Overseas New Drugs Urgently Needed in Clinical Settings by the Center for Drug Evaluation, NMPA in China, and granted for fast-track designation. As a potent and highly selective first-in-class oral IDH1 inhibitor, TIBSOVO was also recommended by the 2020 edition of the CSCO Guidelines for Diagnosis and Treatment of Hematological Malignancies due to its proven clinical advantages. Meanwhile, the NMPA of China has accepted the new drug application (NDA) of TIBSOVO in adult patients with R/R AML who have a susceptible IDH1 mutation and this NDA has been granted priority review.

    About NCT03173248 AGILE Phase 3 AML Trial

    The AGILE trial is a global, Phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial designed to evaluate the efficacy and safety of TIBSOVO in combination with azacitidine compared with placebo in combination with azacitidine, in patients with newly diagnosed IDH1 mutant AML who are not candidates for intensive chemotherapy. The study’s primary endpoint is EFS, defined as the time from randomization until treatment failure, relapse from remission, or death from any cause, whichever occurs first. Treatment failure is defined as failure to achieve complete remission (CR) by Week 24.

    Other key secondary endpoints included complete remission rate (CR rate), defined as the proportion of participants who achieve a CR; overall survival (OS), defined as the time from date of randomization to the date of death due to any cause; CR and complete remission with partial hematologic recovery (CRh) rate, defined as the proportion of participants who achieve a CR or CRh; and objective response rate (ORR), defined as the rate of CR, CR with incomplete hematologic recovery (CRi) (including CR with incomplete platelet recovery [CRp]), partial remission (PR), and morphologic leukemia-free state (MLFS).

    About Acute Myeloid Leukemia

    Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow marked by rapid disease progression and is the most common acute leukemia affecting adults with approximately 20,000 new cases in the U.S., and 43,000 cases in Europe each year3,4. The majority of patients with AML eventually relapse. Relapsed or refractory AML has a poor prognosis5. The five-year survival rate is approximately 27%3. For 6 to 10 percent of AML patients, the mutated IDH1 enzyme blocks normal blood stem cell differentiation, contributing to the genesis of acute leukemia6.

    About TIBSOVO® (ivosidenib tablets)

    TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA-approved test with:

    Acute Myeloid Leukemia (AML)

    • Newly-diagnosed AML who are ≥ 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
    • Relapsed or refractory AML.


    Locally Advanced or Metastatic Cholangiocarcinoma

    • Locally advanced or metastatic cholangiocarcinoma who have been previously treated.


    About CStone

    CStone Pharmaceuticals (HKEX: 2616) is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, CStone has received three drug approvals in Greater China, including two in Mainland China and one in Taiwan. CStone's vision is to become globally recognized as a world-renowned biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.

    For more information about CStone, please visit:

    Forward-looking statement

    The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments.


    1.Data on file. Servier. July 30, 2021 Study of AG-120 (Ivosidenib) vs. Placebo in Combination with Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE). Available at: Accessed July 2021.

    3.National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Acute Myeloid Leukemia (AML). Accessed July 2021.

    4.American Cancer Society. Acute Myeloid Leukemia (AML). Accessed July 2021.

    5.Kumar C. Genetic Abnormalities and Challenges in the Treatment of Acute Myeloid Leukemia. Genes Cancer. 2011; 2:95-107.

    6.DiNardo CD, Stein EM, de Botton S, et al. Durable Remissions from Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med 2018;378:2386-98.

    Your privacy is important for us. We use cookies to enhance your experience when visiting our websites: performance cookies show us how you use this website, functional cookies remember your preferences and targeting cookies help us to share content relevant to you. Select “Accept all” for giving your consent to all cookies or select “Reject all” for using only strictly necessary cookies.